Call us today 212-583-0100

ENZO Biochem Appoints Andrew R. Crescenzo Senior Vice President Of Finance

FARMINGDALE, NY, June 6, 2006 – Enzo Biochem (NYSE:ENZ) today announced the appointment of Andrew R. Crescenzo as Senior Vice President of Finance, a new position.   A CPA, Mr. Crescenzo previously was an Executive Director with the international professional service and accounting firm of Grant Thornton LLP.
 
“With our focus on expanding our Company’s strategic capabilities, I am pleased to welcome Andrew as the newest addition to our executive team.  His more than 20 years experience working with public and private companies will prove valuable as we continue to pursue organic and other avenues of product development and expansion,” said Barry Weiner, President.   “Andrew will be chiefly responsible for the Company’s financial operating activities, which will benefit from his broad knowledge of auditing, financial budgeting, internal controls, planning, M&A transactions, Sarbanes Oxley Act compliance and regulatory filings, among other professional skills.”
 
Mr. Crescenzo joined Grant Thornton in February 1997 as a Senior Manager and for the past five years served as an Executive Director, managing a broad, diversified client base of public and privately owned companies.   From June 1993 to January 1997 he was VP, Chief Financial Officer of J. D’Addario & Company, Inc., where he was responsible for financial management of four companies, and for nine years prior to that was a Senior Manager with the accounting firm of Ernst and Young LLP.
 
He holds a Bachelor of Business Administration-Accounting from Adelphi University, where he is a Board Member of the Alumni Association.  Mr. Crescenzo is also on the Advisory Board of the C.W. Post School of Accountancy, and is a member of the American Institute of CPAs and the New York State Society of CPAs, having served as a past Chairperson of the Nassau Chapter of the New York State Society’s CPA’s in Industry Committee and Accounting and Auditing Committee.    

About Enzo
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn's Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.